<p>This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers.</p>
<p>A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701.</p>

This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701.

CAR T-Cells and Safety Signals

From the New England Journal of Medicine, welcome to “Intention to Treat,” a podcast exploring the most complicated, perplexing, and fascinating issues facing medicine today. From groundbreaking research, to clinical advances, to personal stories from doctors and their patients, we give you a behind-the-scenes look at discoveries that are changing medical practice and provide you with the knowledge to thrive on the front lines of health care.

Share CAR T-Cells and Safety Signals

Sign up to save your podcasts

CAR T-Cells and Safety Signals

CAR T-Cells and Safety Signals

More shows like Intention to Treat

JAMA Editors' Summary

NEJM Interviews

NEJM Journal Watch Podcasts: Clinical Conversations

NEJM This Week

This Week in Cardiology

JAMA Clinical Reviews

Hidden Brain

The Daily

Eagle's Eye View: Your Weekly CV Update From ACC.org

Leadership Conversations

Curbside Consults

Annals On Call Podcast

The Clinical Problem Solvers

Harrison's PodClass: Internal Medicine Cases and Board Prep

Hard Fork

The Rest Is History

NEJM AI Grand Rounds

Not Otherwise Specified